Please ensure Javascript is enabled for purposes of website accessibility

Is Crispr Therapeutics Stock a Bad News Buy?

By George Budwell - May 31, 2018 at 7:55AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

After the FDA put the company's gene-editing product candidate for sickle cell disease on hold, bargain hunters may want to scoop up some shares. Here's why.

What happened

Shares of the gene-editing company Crispr Therapeutics (CRSP -5.41%) fell by more than 14% in pre-market trading today. The culprit?

Crispr and its development partner Vertex Pharmaceuticals (VRTX -3.88%) announced after the bell Wednesday that the Food and Drug Administration (FDA) has placed a clinical hold on the Investigational New Drug (IND) application for their sickle cell disease product candidate, CTX-001. Prior to this hold, CTX-001 was on track to become the first company sponsored CRISPR product candidate to enter human trials in the United States. 

CRISPR (clustered regularly interspaced short palindromic repeats) is a fairly new form of gene-editing that centers around a bacterial enzyme, known as Cas9 (CRISPR-associated protein-9), that modifies the DNA of attacking viruses in nature. 

Shocked young man looking at laptop computer anxious with open mouth.

Image source: Getty Images.

Shares of the two other publicly traded CRISPR companies -- Editas Medicines (EDIT -4.53%) and Intellia Therapeutics (NTLA -2.57%) -- are also both down in pre-market trading (less than 4%) in the wake of this regulatory setback. 

So what

While Crispr and Vertex didn't go into specifics, they did note in their joint press release that the hold stems from "certain questions that will be provided by the FDA as part of its review of the IND." If you've been following this story, however, this hold shouldn't be all that surprising.

Heading into this IND filing, the safety and applicability of current CRISPR gene-editing systems had already been called into question by leading researchers in the field. So the FDA seems to be simply doing its due diligence on this fairly novel technology. 

Now what

Crispr and Vertex are reportedly working with the FDA to obtain more information in order to get this hold lifted. The good news is that the two companies also announced in the same press release that the therapy's European trials for transfusion-dependent beta-thalassemia remain on track to kick off in the second half of 2018 as planned, despite this clinical hold in the United States. As such, Crispr should maintain its first-mover advantage over both Editas and Intellia. 

Is Crispr's stock worth buying on this double-digit pullback? Frankly, I think the answer is yes. The biotech's shares have more than quadrupled in value in the past twelve months in anticipation of this groundbreaking gene-editing trial, and this clinical hold is likely to be nothing more than a cautionary measure by the FDA. Crispr also has a decent chance of grabbing the lion's share of the market well before Editas and Intellia even get their respective platforms into late-stage trials. 

That being said, there is no guarantee this hold will get lifted. So it's probably not a good idea to go hog wild with any of these CRISPR stocks until this key regulatory issue is favorably resolved.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

CRISPR Therapeutics Stock Quote
CRISPR Therapeutics
$63.28 (-5.41%) $-3.62
Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
$276.17 (-3.88%) $-11.15
Editas Medicine, Inc. Stock Quote
Editas Medicine, Inc.
$12.45 (-4.53%) $0.59
Intellia Therapeutics Stock Quote
Intellia Therapeutics
$52.03 (-2.57%) $-1.37

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.